RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyeongmin | - |
dc.contributor.author | Kim, Se Hoon | - |
dc.contributor.author | Lee, Jung-Yun | - |
dc.contributor.author | Kim, Yoo-Na | - |
dc.contributor.author | Lee, Seung-Tae | - |
dc.contributor.author | Park, Eunhyang | - |
dc.date.accessioned | 2024-08-13T09:36:39Z | - |
dc.date.available | 2024-08-13T09:36:39Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.issn | 2005-0399 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26474 | - |
dc.description.abstract | Objective: The RAD51 assay is a recently developed functional assay for homologous recombination deficiency (HRD) that reflects real-time HRD status. We aimed to identify the applicability and predictive value of RAD51 immunohistochemical expression in pre-and post-neoadjuvant chemotherapy (NAC) samples of ovarian high-grade serous carcinoma (HGSC).Methods: We evaluated the immunohistochemical expression of RAD51/geminin/& gamma;H2AX in ovarian HGSC before and after NAC. Results: In pre-NAC tumors (n=51), 74.5% (39/51) showed at least 25% of & gamma;H2AX-positive tumor cells, suggesting endogenous DNA damage. The RAD51-high group (41.0%, 16/39) showed significantly worse progression-free survival (PFS) compared to the RAD51-low group (51.3%, 20/39) (p=0.032). In post-NAC tumors (n=50), the RAD51-high group (36.0%, 18/50) showed worse PFS (p=0.013) and tended to present worse overall survival (p=0.067) compared to the RAD51-low group (64.0%, 32/50). RAD51-high cases were more likely to progress than RAD51-low cases at both 6 months and 12 months (p=0.046 and p=0.019, respectively). Of 34 patients with matched pre-and post-NAC RAD51 results, 44% (15/34) of pre-NAC RAD51 results were changed in the post-NAC tissue, and the RAD51 high-to-high group showed the worst PFS, while the low-to-low group showed the best PFS (p=0.031).Conclusion: High RAD51 expression was significantly associated with worse PFS in HGSC, and post-NAC RAD51 status showed higher association than pre-NAC RAD51 status. Moreover, RAD51 status can be evaluated in a significant proportion of treatment-naive HGSC samples. As RAD51 status dynamically changes, sequential follow-up of RAD51 status might reflect the biological behavior of HGSCs. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY | - |
dc.title | RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3802/jgo.2023.34.e45 | - |
dc.identifier.scopusid | 2-s2.0-85164241193 | - |
dc.identifier.wosid | 001037079300004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, v.34, no.4 | - |
dc.citation.title | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.volume | 34 | - |
dc.citation.number | 4 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002974366 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | REPAIR | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | REVERSION | - |
dc.subject.keywordPlus | GERMLINE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | BRCA1 | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordAuthor | Ovarian Cancer | - |
dc.subject.keywordAuthor | RAD51 recombinase | - |
dc.subject.keywordAuthor | Homologous Recombination | - |
dc.subject.keywordAuthor | Neoadjuvant Chemotherapy | - |
dc.subject.keywordAuthor | Immunohistochemistry | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.